Novo Nordisk logo

Novo Nordisk(NYSE) NVO

Market Cap$131.66BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1981)+35,578%
5 Year-17%
1 Year-25%
1 Month-2%
Premium Feature
Moneyball Superscore
78/100
$39.08
-0.70%
-0.28Today
After hours$39.06-$0.01 (-0.04%)
Novo Nordisk last closing stock price
MetricPriceDate
Last closeUSD 39.062026-10-21
Novo Nordisk stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.47%USD 38.122026-10-14
1 month-1.86%USD 39.802026-09-21
3 month-17.89%USD 47.572026-07-23
Year to date-19.53%USD 48.542025-12-31
1 year-25.26%USD 52.262025-10-21
3 year-55.8%USD 88.372023-10-20
5 year-17.47%USD 47.332021-10-22
Since inception+35,577.97%USD 0.111981-07-09

Novo Nordisk Financials at a Glance

Market Cap

$131.66BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

DKK 329.43B

Net Income (TTM)

DKK 116.44B

EPS (TTM)

$4.09

P/E Ratio

9.61

Dividend

$1.80

Beta (Volatility)

0.68 (Low)

Price

$39.08

Volume

6,797,307.52

Open

$39.25

Previous Close

$39.06

Daily Range

$39.05 - $39.49

52-Week Range

$35.12 - $64.16

Estimated Earnings Date

Nov 4, 2026

NVO News

Novo Nordisk logo source-TMF

Where Will Novo Stock Be in 10 Years?

Prosper Junior BakinyOct 21, 2026
drug development pharmaceutical pharma research researchers doctors.jpg

Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?

Eric VolkmanOct 21, 2026
Pills on money

How to Buy Novo Nordisk Stock (NVO) in 2026

Matt DiLalloOct 19, 2026
Novo Nordisk logo source-TMF

Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?

Prosper Junior BakinyOct 18, 2026
GettyImages-1300205240

Novo Nordisk and Eli Lilly Just Got Some Fantastic News

Matthew BenjaminOct 16, 2026
Healthcare - GettyImages-1431433562-1601x1065-88e537c.jpg

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Brendan CoffeyOct 13, 2026
pills money .jpg

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Brendan CoffeyOct 10, 2026
26_10_08 A roll of money sitting in a mouse trap _MF Dload risk-1281x830-f009afd

UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.

Reuben Gregg BrewerOct 8, 2026
Page 1

NVO: Motley Fool Moneyball Superscore

78

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novo Nordisk

Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products. The company operates primarily in the Diabetes and Obesity Care, and Rare Disease sectors, with a strong international presence.

Products and Services
  • Diabetes and obesity therapies, including insulin and GLP-1 receptor agonists
  • Treatments for rare blood disorders and hormone replacement solutions
  • Smart digital solutions for diabetes management, such as advanced insulin pens
Growth Outlook
  • Projected revenue growth driven by increasing diabetes prevalence globally
  • Expansion into emerging markets, particularly in Asia and Africa
  • Strategic partnerships enhancing research and development capabilities
Financial Highlights
  • Recent quarterly revenue of 78.49 billion DKK, reflecting strong demand
  • Trailing twelve months (TTM) net income margin of 35.35%, indicating profitability
  • Dividend yield of 4.51%, showcasing commitment to returning value to shareholders
Novo Nordisk A/S has established itself as a leader in the pharmaceutical industry, particularly in diabetes care. The company's innovative products and strategic focus on rare diseases position it well for future growth. Recent financial performance highlights a robust revenue stream and strong profit margins, underscoring the company's operational efficiency. With a commitment to research and development, Novo Nordisk is poised to capitalize on the growing global demand for diabetes and obesity treatments. The company's strategic alliances further enhance its capabilities, making it an attractive option for potential investors.
AI Generated • Oct 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

68,794

CEO

Maziar Mike Doustdar

Website

www.novonordisk.com

Headquarters

Bagsvaerd, CR 2880, DK

NVO Financials

Key Financial Metrics (TTM)

Gross Margin

80.65%

Operating Margin

43.13%

Net Income Margin

35.35%

Return on Equity

59.09%

Return on Capital

39.28%

Return on Assets

19.57%

Earnings Yield

10.41%

Dividend Yield

4.57%

Payout Ratio

44.64%

Stock Overview

Market Cap

$131.66BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.35B

Volume

6.80M

Avg. Volume

12.79M

Financials (TTM)

Gross Profit

DKK 265.68B

Operating Income

DKK 142.10B

EBITDA

DKK 180.91B

Operating Cash Flow

DKK 133.01B

Capital Expenditure

-DKK 84.09B

Free Cash Flow

DKK 48.92B

Cash & ST Invst.

DKK 44.98B

Total Debt

DKK 140.13B

Novo Nordisk Performance Analysis

Novo Nordisk annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31DKK 24,998,461,07711.7%
20232023-12-31DKK 33,700,297,29934.8%
20242024-12-31DKK 42,115,001,36325.0%
20252025-12-31DKK 46,735,785,02911.0%
Novo Nordisk sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-2.4%
Q42025-12-315.6%
Q12026-03-3122.3%
Q22026-06-30-18.9%
Novo Nordisk annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31DKK 1.734.7%
20232023-12-31DKK 2.7056.5%
20242024-12-31DKK 3.2821.5%
20252025-12-31DKK 3.486.1%
Novo Nordisk sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-24.5%
Q42025-12-3134.2%
Q12026-03-3180.6%
Q22026-06-30-56.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

DKK 78.49B

+2.1%

Gross Profit

DKK 61.39B

-4.1%

Gross Margin

78.21%

N/A

Market Cap

$131.66BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.91M

N/A

Employees

68,794

N/A

Net Income

DKK 20.99B

-20.8%

EBITDA

DKK 38.68B

-11.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

DKK 44.98B

+137.6%

Total Debt

DKK 140.13B

+41.2%

Accounts Receivable

DKK 108.51B

+26.4%

Inventory

DKK 51.35B

+12.5%

Long Term Debt

DKK 121.79B

+39.5%

Short Term Debt

DKK 18.33B

+53.2%

Return on Assets

19.57%

N/A

Return on Invested Capital

39.93%

N/A

Free Cash Flow

DKK 42.40B

+73.0%

Operating Cash Flow

DKK 55.20B

+35.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNYSanofi
$40.97-1.04%
GSKGSK plc
$50.02-1.20%
PFEPfizer Inc.
$29.86-0.83%
AMGNAmgen Inc.
$438.34-0.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$159.31+7.80%
NFLXNetflix
$65.04-5.31%
NVDANvidia
$221.97+2.54%
TAT&T
$21.91-6.45%

Questions About NVO

What is the current price of Novo Nordisk?

Novo Nordisk is trading at $39.06 per share.

What is the 52-week range for Novo Nordisk?

Over the past 52 weeks, Novo Nordisk has traded between $35.12 and $64.16.

How much debt does Novo Nordisk have?

As of the most recent reporting period, Novo Nordisk reported total debt of DKK 21.43B.

How much cash does Novo Nordisk have on hand?

Novo Nordisk reported DKK 6.80B in cash and cash equivalents in its most recent financial results.

What is Novo Nordisk’s dividend yield?

Novo Nordisk currently has a dividend yield of 4.57%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services